Literature DB >> 10593969

Characterization and properties of dominant-negative mutants of the ras-specific guanine nucleotide exchange factor CDC25(Mm).

M Vanoni1, R Bertini, E Sacco, L Fontanella, M Rieppi, S Colombo, E Martegani, V Carrera, A Moroni, C Bizzarri, V Sabbatini, M Cattozzo, A Colagrande, L Alberghina.   

Abstract

Ras proteins are small GTPases playing a pivotal role in cell proliferation and differentiation. Their activation depends on the competing action of GTPase activating proteins and guanine nucleotide exchange factors (GEF). The properties of two dominant-negative mutants within the catalytic domains of the ras-specific GEF, CDC25(Mm), are described. In vitro, the mutant GEF(W1056E) and GEF(T1184E) proteins are catalytically inactive, are able to efficiently displace wild-type GEF from p21(ras), and strongly reduce affinity of the nucleotide-free ras x GEF complex for the incoming nucleotide, thus resulting in the formation of a stable ras.GEF binary complex. Consistent with their in vitro properties, the two mutant GEFs bring about a dramatic reduction in ras-dependent fos-luciferase activity in mouse fibroblasts. The stable ectopic expression of the GEF(W1056E) mutant in smooth muscle cells effectively reduced growth rate and DNA synthesis with no detectable morphological changes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593969     DOI: 10.1074/jbc.274.51.36656

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Ras guanine nucleotide releasing factor 1 (RasGrf1) enhancement of Trk receptor-mediated neurite outgrowth requires activation of both H-Ras and Rac.

Authors:  Asghar Talebian; Kim Robinson-Brookes; James I S MacDonald; Susan O Meakin
Journal:  J Mol Neurosci       Date:  2012-06-29       Impact factor: 3.444

2.  Activation of amyloid precursor protein processing by growth factors is dependent on Ras GTPase activity.

Authors:  Loredana Amigoni; Michela Ceriani; Fiorella Belotti; Giuseppina Minopoli; Enzo Martegani
Journal:  Neurochem Res       Date:  2010-12-15       Impact factor: 3.996

3.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Authors:  Stefania Fasano; Erwan Bezard; Angela D'Antoni; Veronica Francardo; Marzia Indrigo; Li Qin; Sandra Doveró; Milica Cerovic; M Angela Cenci; Riccardo Brambilla
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

4.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Authors:  Daniela Gaglio; Christian M Metallo; Paulo A Gameiro; Karsten Hiller; Lara Sala Danna; Chiara Balestrieri; Lilia Alberghina; Gregory Stephanopoulos; Ferdinando Chiaradonna
Journal:  Mol Syst Biol       Date:  2011-08-16       Impact factor: 11.429

5.  Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts.

Authors:  Daniela Gaglio; Chiara Soldati; Marco Vanoni; Lilia Alberghina; Ferdinando Chiaradonna
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

6.  Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling.

Authors:  Lilia Alberghina; Daniela Gaglio; Cecilia Gelfi; Rosa M Moresco; Giancarlo Mauri; Paola Bertolazzi; Cristina Messa; Maria C Gilardi; Ferdinando Chiaradonna; Marco Vanoni
Journal:  Front Physiol       Date:  2012-09-12       Impact factor: 4.566

7.  The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors.

Authors:  Teklab Gebregiworgis; Yoshihito Kano; Jonathan St-Germain; Nikolina Radulovich; Molly L Udaskin; Ahmet Mentes; Richard Huang; Betty P K Poon; Wenguang He; Ivette Valencia-Sama; Claire M Robinson; Melissa Huestis; Jinmin Miao; Jen Jen Yeh; Zhong-Yin Zhang; Meredith S Irwin; Jeffrey E Lee; Ming-Sound Tsao; Brian Raught; Christopher B Marshall; Michael Ohh; Mitsuhiko Ikura
Journal:  Nat Commun       Date:  2021-11-01       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.